Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Open-label Extension Study to Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

NCT05332210 is registered in ClinicalTrials.gov with Harbour BioMed (Guangzhou) Co. Ltd. as lead sponsor.

NCT NCT05332210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05332210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Open-label Extension Study to Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Lead sponsor
Harbour BioMed (Guangzhou) Co. Ltd.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2022
Completion date
April 26, 2024
Enrollment
111 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myasthenia gravis